Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs.
England’s NHS to Offer Eli Lilly Obesity Drug to Some Patients
Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years as part of a phased rollout of the popular drug.
Eli Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.'s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when patients couldn't find the brand-name medicines.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The announcement is a blow to the compounding pharmacies that have made cheaper, off-brand versions of the medication The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over,
Shortage of Eli Lilly’s Weight-Loss, Diabetes Drugs Is Over
The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making custom-made versions.
England's NHS to offer Lilly's weight-loss drug to some patients
England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,
Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List
Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Facebook has become the place to sell leftover Ozempic, other weight loss drugs — as NYC sellers take advantage of shortages and high prices
God knows what volume they’re actually selling. And who knows? You’re just taking it,” one expert told The Post.
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Hosted on MSN5h
NHS to roll out Mounjaro weight loss jab to 1.6 million patients
In a phased rollout, the jabs eventually will be offered to those with a BMI of 35 or more and weight-related health problems ...
scrippsnews1h
FDA says shortage of popular diabetes, weight-loss drugs resolved
The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...
FDA makes end of Zepbound, Mounjaro shortage official
Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded ...
'King Kong' of weight loss jabs Mounjaro to be rolled out on the NHS to tackle obesity
NHS says a quarter of a million people will be offered tirzepatide - brand name Mounjaro - after trials showed it helped obese participants lose a fifth of their body weight ...
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.